People | January 04, 2026
AstraZeneca elevates Vikram Chand as SVP, Head of R&D for Japan
Dr. Chand held several leadership positions within AstraZeneca and the broader biopharmaceutical industry
Dr. Chand held several leadership positions within AstraZeneca and the broader biopharmaceutical industry
Cupid is strengthening its footprint in the GCC region, focusing on supply responsiveness and market proximity
The partnership also sets the stage for broader collaboration on rare disease treatments
Nona aims to help global biopharmaceutical companies fast-track clinical trial initiation without compromising scientific rigor or quality standards
The drug had previously received orphan drug designation for this rare cancer on March 31, 2025
The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies
Under the terms of the deal, AstraZeneca gains exclusive rights to JAB-23E73 outside of mainland China
Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients
Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized
The expansion includes a larger technical and service team and increased local procurement
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
